

ASGO Education Webinar

2025/6/26

Department of Obstetrics and Gynecology,
St. Marianna University School of Medicine

Jun Takeuchi

Q1. Are there any clinical trials planned for ARID1A with mutations in clear cell carcinoma or endometrioid carcinoma?

ARID1A has been associated with PD-L1 and high TMB mutations, and I believe that treatment leading to synthetic lethality, similar to BRCA, may be possible for ovarian cancer with ARID1A mutations.

Q2. Is there any evidence supporting the re-administration of platinum-based therapy after a 6-month or longer interval following platinum resistance in recurrent ovarian cancer?

Q3. Is it possible for our ASGO team to propose clinical trials in various countries in the future?